Department of Health and Human Services, through National Institutes of Health, awarded Janusq LLC of Rocky River, OH $698,011 under the SBIR program, with work starting 2025-09-15 and running to 2027-02-28. It is one of 2 SBIR and STTR awards Janusq LLC received in the last two years, $1,274,675 in all. Each figure links to the federal record.
The award
| Recipient | Janusq LLC (Rocky River, OH) |
|---|---|
| Awarding agency | Department of Health and Human Services |
| Awarding office | National Institutes of Health |
| Amount obligated | $698,011 |
| Period of performance starts | 2025-09-15 |
| Period of performance ends | 2027-02-28 |
| Award number | R43NS145846 (grant, CFDA 93.853) |
| Assistance listing | 93.853, Extramural Research Programs in the Neurosciences and Neurological Disorders |
| Place of performance | Rocky River, Cuyahoga County, OH |
| Signed | 2025-09-12 |
| Recipient registry id (UEI) | DKRHA61KMNX4 |
Want the whole picture on Janusq LLC?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Janusq LLC: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Janusq LLC covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
2 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
What it is for
In vivo efficacy and in vitro toxicity assessment of peptide-based therapy HV-3 for the treatment of huntington's disease - project summary/abstract janusq, llc—a startup biotech company spun out of case western reserve
Funding actions on this award
| Date | Action | Modification | Amount |
|---|---|---|---|
| 2026-08-07 | Continuation | 000 | $207,510 |
| 2025-09-12 | New | 000 | $490,501 |
In vivo efficacy and in vitro toxicity assessment of peptide-based therapy HV-3 for the treatment of huntington's disease - project summary/abstract janusq, llc—a startup biotech company spun out of case western reserve university—is developing a peptide-based therapy for the treatment of mitochondrial dysfunction in huntington’s disease (hd). This neurological disorder affects 30,000 diagnosed patients in the US, with 150,000 more at risk. No proven, effective treatments for hd exist, and patients are relegated to therapies that lessen involuntary muscle movements and behavioral changes. Therapies that address the causative agent, the mutant huntingtin protein (mthtt), have not yet seen success in the clinic, and the mechanism by which mthtt leads to the disease state is poorly understood. Mutant huntingtin associates with mitochondria, triggering dysfunction that leads to neurotoxicity. In multiple hd models, valosin-containing protein (vcp) is recruited to mitochondria, where vcp associates with mthtt and leads to excessive mitophagy and neuronal death. A newly designed peptide, HV-3, disrupts vcp-mthtt interactions, reducing aberrant mitophagy and improving neuronal survival. In hd animal models, HV-3 reduces behavioral and neuropathological phenotypes and improves survival. Janusq recently developed robust methods for quantitating HV-3 from plasma and brain tissue, and inv ...
From the federal award record.
Other SBIR and STTR awards to Janusq LLC
| Starts | Agency | Program | Amount | Project |
|---|---|---|---|---|
| 2025-09-22 | Department of Health and Human Services | SBIR | $576,664 | Pharmacokinetics and in vivo efficacy of DA1 macrocyclic peptides in a murine model of alz (record) |
Who runs it, who owns it, where the money comes from and what to watch for, every claim linked to its source.
Order Full Report on Janusq LLCLook up Janusq LLC and see what is on record before you decide.
Get the free SnapshotWhere this comes from
The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs set aside part of federal research budgets for small companies. Agencies award them in phases: Phase I tests whether an idea is feasible, Phase II funds development, and Phase III is follow-on work paid for outside the set-aside. STTR awards also require a research institution as a partner.
Every figure on this page is taken from the award's own federal record, linked beside it, as it stood when the page was built: the recipient, its address, the awarding agency and office, the amount obligated so far, the dates and the description. Phase and program are shown as the award's own description states them. The amount can grow later if the agency adds funding to the same award.